Tags Posts tagged with "ogrmf"

ogrmf

0 3149

Canada is set to make history this week by tabling legislation that would make the nation the first G-7 country to legalize recreational cannabis.

This development has captured the attention of the market and many investors are focusing on companies levered to this opportunity. We want to highlight two Canadian companies that investors should be monitoring closely.

OrganiGram Announces LOI with Trauma Healing Centers

Organigram Holdings (OGI.V) (OGRMF), a licensed medical cannabis producer in Canada announced that it entered a letter of intent to acquire all the issued and outstanding shares of Trauma Healing Centers Incorporated. Under the terms of the LOI, Organigram will issue 719,425 common shares at $2.78 per share to the company.

Trauma Healing Centers currently services over 3,500 patients across 7 Canadian locations and it has plans to open 7 more locations. The company specializes in medical cannabis assessment and prescribing. Trauma sees patients on a referral basis and offers a multi-disciplinary approach to healing chronic conditions.

Trauma Healing Centers will continue to operate independently by providing referrals based on client need to any licensed producer in Canada. The company is the only organization to have a multi-disciplinary designation with Blue Cross for military and RCMP veteran clients.

We favorable on this development due to the potential synergies between the two companies. Also, the $2 million purchase price is attractive when compared to similar transactions. OrganiGram has rallied off its recent lows and this is a company that should be on every investor’s radar.

Canabo Announces Groundbreaking Results

On Friday, Canabo Medical (CMM.V: TSX Venture) (CAMDF: OTCQB) released the results of an observational study that connected doctor-supervised medical cannabis treatments to a decrease in benzodiazepine reliance among Canadian patients.

Research conducted over the past year revealed that 40% of patients who were prescribed medical cannabis to treat pain and anxiety eliminated the use of benzodiazepines within 90 days. The number of patients that stopped using benzodiazepines increased to 45% within a year of cannabis treatment.

 

1 4979

Last month, on October 3, 2016, we published an article titled Past, Present, & Future of Canadian Marijuana Stocks where we expressed our bullish sentiment on the Canadian marijuana sector and identified a list of stocks to consider. In the article, we named 6 companies to focus on. Within one month of publishing the article, those 6 stocks have seen combined 480% in total gains as of November 2nd, 2016. This article would have been out a week ago if our new intern knew how to hit the publish button correctly. Regardless, the gains and the charts do not lie as they tell the tale of the ticker tape.
The Canadian government is planning to legalize cannabis in spring 2017 and the number of Canadian medical marijuana patients is expected to more than double. This will tilt the supply and demand scale for medical marijuana largely in favor of demand. We do not believe this recent rally to be just a pre-election “hype rally.” This is the coming out party for an industry with an immensely bright future and staying power.
Licensed medical cannabis producers have raised more than $100 million in the past couple months to be used to support growth initiatives like mergers and acquisitions and facility expansions to better meet the increased demand. The investment opportunities in the legal cannabis industry have proven extremely lucrative to informed investors. Let’s take a look at the 6 companies we highlighted in our October 3rd article to see how they are doing today and where they could go from here.
1. Canopy Growth Corporation (CGC.TO)(TWMJF)

pic1

 

 

Canopy Growth is the largest legal medical marijuana producer in Canada and has been one of the most attractive investment opportunities in the cannabis sector since going public in 2014. CGC.TO hit a high of $7.35 on October 20th for an 80.5% gain from our initial article publication. The stock closed trading today at $6.55, still up 61%. TWMJF (the US OTC listing) still sits up 58% today.

Canopy Growth is the medical marijuana industry leader. Aside from individual news announcements, expect other marijuana companies to follow the strength and/or weakness of CGC.TO. After a healthy pull-in, the stock held support around $5.50 and remains in a strong uptrend.

2. Aurora Cannabis (ACB.CN)(ACBFF)

pic2

Aurora Cannabis is one of the fastest growing licensed medical cannabis producers in Canada. One thing to know about them is that they recently did a private placement for $20,000,000 and ended up being over-subscribed by a few million dollars. They have one of the industry’s more impressive facilities and is partly why we added Aurora to our Focus List in June 2016. Since July of 2016, ACBFF is up roughly 125%. And since our article publication on October 3rd, ACBFF gained as much as 78% and closed trading today around $1.66, still up nearly 57%.

ACBFF is forming a bullish pennant pattern that would trigger a long through the $1.77 area or a sell below the $1.50 area. A breakdown of the pattern could see ACBFF test the gap it put in place on October 5th. However, a healthy consolidation in this range would give the moving averages time to catch up while the stock takes a breather before a possible move higher into $2.00 land.

3. Aphria Inc. (APH.V)(APHQF)

pic3

Aphria showed the smallest gain potential of all the companies listed in our October 3rd article. A max 17% gain was possible while APH closed trading today at $3.80, still up 10%.

APH.V has put in a double top at $4.00 that would act as a trigger long if broken to the upside. Support is in place around $3.30 after being tested multiple times and holding over the past month. A break below this support could see Aphria test its next support area around $3.00.

4. OrganiGram Holdings (OGI.V)(OGRMF)

pic4

Organigram is the second largest licensed producer in Canada and was the first to report positive cash flow. Organigram could be considered the second industry leader behind Canopy Growth so it is no surprise to see the two share very similar chart patterns. OGI.V hit a high of $3.11 on October 19th for a 75% gain from our article publication and closed trading today at $2.76, still up 55%.

Like CGC.TO, Organigram remains in an uptrend. Support was put in around the $2.30 area after a healthy pull-in. Look for OGI.V and CGC.TO to show strength and weakness together. It would be rare for one to show strength while the other weakness (unless for an individual press release good or bad).

5. Arcturus Growthstar Technologies (AGS.CN)(AGSTF)

pic5

Arcturus Growthstar Technologies is a company that may play a huge part in the expansion of the Canadian cannabis market and its ability to meet the increased demand. Their Controlled Environment Agriculture technology helps producers minimize land, water, and energy output while increasing crop turnover and capacity.

We also published a Connect the Dots piece on AGSTF on October 4th to introduce our readers to a new company that we believed was worth considering. The stock gained a remarkable 180% in just three days before pulling back in to still be up 34%. For those unfamiliar with Arcturus, we recommend going back and reading our Connect the Dots piece published on October 4th.

It’s important to discuss why such a sharp pullback after the 180% run. And we believe there to be a couple reasons.

➢ The stock is a very new issue and, therefore, does not have as much of a trading history as some of the other companies on this list. The trading float is also much smaller than the Canadian companies that came public in 2014 or sooner. This can sometimes result in over exaggerated or over extended price movements in both directions because of lack of stock available in the open market.

➢ The Company had a million dollars of warrants exercise at $0.15 to raise additional capital to support their rapid growth and expansion. Although it brought cash to the company, it added pressure to the market that aided in the sharp pull-in. But with that exercise now behind them, Arcturus can focus on putting that money to work.

Don’t forget, in October 2015, one year ago, Organigram traded for less than $0.30 a share, too. Fast forward to October 2016 and the stock now trades for $2.75 a share. Good management can build shareholder value pretty quickly when appropriating funds correctly and progressing through their business plan. And the management team behind Arcturus is one of the main reasons why we decided to issue a Connect the Dots piece on the company.

6. Cronos Group (formerly PharmaCan Capital Corp.) (MJN.V)(PRMCF)

pic6

Cronos Group is an investment firm and holding company for Licensed Producers under Canada’s Marihuana for Access to Cannabis for Medical Purposes Regulations (“ACMPR”). With interests in five licensed producers and three license applicants, Cronos Group is focused on building iconic brands providing patients with compassionate, personalized care. The stock hit a high of $1.35 on October 6th for a 45% gain from our article publication and currently still sits up 29%.

Similar to Aurora Cannabis, Cronos has developed a bullish pennant pattern. The $1.30 area would be a trigger long while the $1.13 area a trigger sell. A breakout could see MJN.V run to the $1.60 area while a breakdown would most likely retest the $1.00 mark, maybe lower.
Conclusion

The timing of our article titled Past, Present, & Future of Canadian Marijuana Stocks was spot on. We nailed breakout points in most of the major Canadian cannabis companies. After publication, the 6 stocks highlighted gained a combined total of 480% and each one remains higher today.

As we mentioned in the article, we believe the Canadian market to be much further along in development than the US market; although the US market is making major strides that we will discuss in a future article. The overall marijuana industry is experiencing a strong rally, both in the US and Canada. And we believe the companies discussed in this piece to have long-term investment potential, not just a quick trade.

    1 4480

    Meet Matt McCall & Get His New PREMIUM Feb. 2015 Newsletter Right Now For Free!

    Inside Matt McCall Discusses $CGRW, $CNAB, $OXIS & $OGRMF

    Download By Clicking Here

    About Matt McCall:

    Matt McCall is the founder and president of Penn Financial Group, an investment advisory firm. Matt is also the Managing Editor MarkETForce and FUTR Stocks. Matt has authored two investment books published by Wiley “The Swing Trader’s Bible” and “The Next Great Bull Market”. Matt is also a contributing writer for Benzinga.com. Matt has over 1200 television appearances in the last seven years and is currently a contributor for Fox Business and Fox News Channel. He appears daily as a panelist from 6-7pm ET on Fox Business Network’s “Making Money with Charles Payne”. As a highly sought after speaker, Matt has keynoted investment conferences in the U.S. and Europe over the last decade.

    1 1397

    Organigram Provides Shareholder Update

    MONCTON, NEW BRUNSWICK–(Marketwired – Jan 20, 2015) – OrganiGram Holdings Inc.(TSX VENTURE:OGI)(OGRMF) (the “Company“) is pleased to provide an update to shareholders while reviewing milestones of 2014 and looking at the growth and goals of 2015.

    Since the inception of Organigram in April 2014, the Company has been growing and developing at a very fast pace. Through this growth, there have been some tremendous achievements, which include receiving our organic certification, producing our first crops, listing of shares on the TSX Venture and completing three phases of construction. Organigram is excited to capitalize on these achievements and execute on the our business plan

    Moving forward, our shareholders, patients and partners will begin to see the results from the foundation laid in 2014. To date, the company has been extremely focused on expanding the production facility while, at the same time, working to increase production levels. These efforts will begin to provide significant product to the market in March of this year. Thereafter, the utilization of our existing rooms and rooms under construction will ensure that Organigram is poised to meet our financial goals in 2015.

    Organigram would like to take this opportunity to congratulate Trauma Healing Centers on the opening of their first clinic, in Halifax, NS. Organigram is proud to be partnered with Trauma Healing Centers on research initiatives to assist our Veterans and others suffering with PTSD.

    Organigram’s CEO, Denis Arsenault states, “Over the past few months, Organigram has moved into a “best in class” manufacturing facility. Our processes and systems have been developed to a point where we produce high quality products, in an organic form, which has and will continue to exceed the requirements of our clients. While we continue to evolve and improve, our facility will begin to supply the market with an established source of product on a consistent basis. We have a superior management team in place that is not only focused on supply but also quality, efficiency and product development. The results of our efforts will not only be very profitable for the company and shareholders but most importantly will provide a rapidly increasing client base with a medicinal product that assists in a much-improved quality of life for many. The developments of the next few weeks and months will be both exciting and fruitful for our company.”

    About Organigram Holdings Inc.

    Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Marihuana for Medical Purposes Regulations.

    On behalf of the board of directors,

    Denis Arsenault, Director and CEO

    Organigram Holdings Inc.

    For further information please visitwww.organigram.ca.

    The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

    This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors – including the availability of funds, the results of financing efforts, the results of exploration activities — that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Contact:
    Brett Allan
    Dir. Of Investor Relations
    OrganiGram Holdings Inc.
    (416) 907-4148

    0 1103

    OrganiGram Obtains $2.5M Loan From Farm Credit Canada & Announces Closing of Equity Financing of $1.4M

    MONCTON, NEW BRUNSWICK–(Marketwired – Dec 22, 2014) – OrganiGram Holdings Inc. (TSX VENTURE:OGI)(OGRMF) (the “Company“) is pleased to announce that it has completed the purchase of its current facility as well as the adjoining building and land. The Company has secured a loan from Farm Credit Canada (“FCC“) in the amount of $2.5M, which has been used to finance 100% of the purchase costs.

     The purchase of the two buildings is a great milestone for the Company and another step forward in advancing the Company’s accelerated facility expansion, which has been initiated in order to keep pace with the higher than expected demand for product.

    Facility Highlights:

    • Two properties total 5.5 acres
    • 78,500 square feet of growing space
    • Completed site build out capacity of 15,000kg

    Building Purchase and Debt Financing Details

    The buildings were purchased for $1,535,000 and $975,000 respectively. The Company has secured debt financing from Farm Credit Canada for 100% of the purchase cost. The debt facility was secured at an interest rate of 5.75% for a term of 5 years.

    Equity Financing

    The company is also pleased to announce that it has, further to its news release dated December 5, 2014, closed a brokered private placement (the “Brokered Financing“) of units (the “Units“) for aggregate gross proceeds of $1,407,417.90 million based on the sale of approximately 2,010,597 Units at a price of $0.70 per Unit. Each Unit is comprised of one common share in the capital of the Company (a “Share“) and one common share purchase warrant (a “Warrant“), each Warrant entitling the holder thereof to acquire an additional share for a period of three years at a price of $1.00 per share. The closing is subject to the fulfillment of certain conditions, including customary post-closing filings with the TSX Venture Exchange.

    The Company engaged Jacob Securities Inc. (“Jacob“) to act as agent on a commercially reasonable efforts basis in connection with the Brokered Financing. As compensation for acting as agent, Jacob received a cash commission (the “Agent’s Commission“) equal to 6% (3% for Units issued through a President’s list) of the gross proceeds raised, and compensation options (the “Agent’s Options“) entitling the agents to purchase Units (the “Agent’s Units“) of the Company equal to 6% (3% for President’s list) of the number of securities sold in the Brokered Financing, exercisable at a price of $0.70 per Agent’s Unit and expiring 24 months from closing of the Brokered Financing. The Agent’s Units have the same terms and conditions as the Units purchased by subscribers in the Brokered Financing.

    The non-brokered private placement financing (the “Non-brokered Financing“) of Units was for an aggregate gross proceeds of $472,993.50 based on the sale of approximately 675,705 Units at a price of $0.70 per Unit. In connection with the Non-brokered Financing, the Company paid an aggregate of $6,300 in finder’s fees, and issued finder’s options (the “Finder’s Options“) entitling finders that assisted with the Non-brokered Financing to purchase an aggregate of 4,500 Units (the “Finder’s Units“). The Finder’s Options are exercisable at a price of $0.85 per Finder’s Option and expire 24 months from closing of the Non-brokered Financing. The Finder’s Units have the same terms and conditions as the Units purchased by subscribers in the Non-brokered Financing.

    The Units, Warrants, Agent’s Units and Finder’s Options (including the underlying common shares and warrants) issued under the Brokered Financing and the Non-brokered Financing are subject to a four-month hold period, which expires April 23, 2015. The closing is subject to the fulfillment of certain conditions, including customary post-closing filings with the TSX Venture Exchange.

    Prior to these two financings, the company had sufficient capital to execute on its previously stated business plan. The capital secured from both these debt and equity financings will be instrumental in helping the Company to produce even greater quantities of high quality, consistent and organic product to satisfy even greater demand it is realizing for its products. These financings will also provide greater control over the main operating assets of the Company.

    About Organigram Holdings Inc.

    Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Marihuana for Medical Purposes Regulations.

    On behalf of the board of directors,

    Denis Arsenault, Director and CEO, Organigram Holdings Inc.

    For further information please visit www.organigram.ca.

    The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors – including the availability of funds, the results of financing efforts, the results of exploration activities – that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Contact:
    OrganiGram Holdings Inc.
    Brett Allan
    Dir. Of Investor Relations
    (416) 907-4148
    www.organigram.ca

    0 1461

    OrganiGram Announces Brokered Private Placement

    MONCTON, NEW BRUNSWICK–(Marketwired – Dec 5, 2014) – OrganiGram Holdings Inc. (TSX VENTURE:OGI)(OGRMF) (the “Company“) is pleased to announce that it has engaged Jacob Securities Inc. (the “Agent”) in connection with a proposed private placement (the “Offering), on a best efforts basis, whereby the Company intends to raise aggregate gross proceeds of a minimum of $4,000,000 and up to $6,000,000 at a price of $0.85 per unit. There is also an over-allotment option exercisable by the Agent prior to and for a period of 30 days following the Closing Date to raise additional gross proceeds of up to 15% of the maximum Offering.

    Each unit will be comprised of one common share and one common share purchase warrant (the “Warrants”). Each Warrant will entitle the holder to purchase one additional common share of the Corporation at a price of $1.00 per share for a period of 36 months from the date of issue.

    The Company will pay the Agent a commission of 6% cash (3% for Units issued through a Presidents List) on gross proceeds raised through the sale of the Units and issue broker warrants to acquire 6% (3% for Presidents List) of the total number of units issued, under this Offering. Each broker warrant will entitle the holder to subscribe for one common share of the Corporation at a price of $1.00 for a period of 24 months from the date of issue.

    Proceeds from this Offering will be used by the Company to expedite the expansion of its medical marijuana facility in order to keep pace with the increase in demand for its products.

    The anticipated closing of the Offering is December 12, 2014 (or such other date as may be agreed upon by the Company and the Agent).

    Completion of this placement is subject to the approval of the TSX Venture Exchange.

    About Organigram Holdings Inc.

    Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Marihuana for Medical Purposes Regulations.

    Please visit www.organigram.ca for more information.

    On Behalf of the Board of Directors of Organigram,

    Denis Arsenault, Director & CEO

    Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors – including the availability of funds, the results of financing efforts, the results of exploration activities — that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Contact:
    OrganiGram Holdings Inc.
    Brett Allan
    Director of Investor Relations
    (416) 907-4148
    brett@organigram.ca

    1 1514

    OrganiGram Announces Three Additional Grow Rooms Pass Inspection – Increase Production

    MONCTON, NEW BRUNSWICK–(Marketwired – Dec 1, 2014) – OrganiGram Holdings Inc. (TSX VENTURE:OGI)(OGRMF) (the “Company“) is pleased to announce, as part of the ongoing expansion at its medical marijuana production facility in Moncton, the Company has completed the construction of 3 additional, 72 flowering light, grow rooms. In accordance with the Marihuana for Medical Purposes Regulations, all necessary Health Canada inspections and approvals have been obtained.

    The completion of the 3 new grow rooms will add 1,700 plants to the facility, enabling the Company to increase production levels to 1,000,000 grams (1,000 kilograms) and represents approx. $8,000,000 in revenue per year.

    “We are extremely happy to be making this announcement today. The Organigram team has been working tirelessly to bring these new grow rooms online and fulfill our commitment to MMPR patients,” said Denis Arsenault, Chairman & CEO.

    Expansion Update

    Additionally, the company began construction of a further 8 grow rooms on October 1, 2014. The construction of these 90 flowering light rooms is expected to be complete and production to begin in February 2015. Once completed, this phase of expansion will add 11 grow rooms totaling 936 flowering lights to the current facilities capacity. This expansion will increase the facility’s production to 3,000,000 grams (3,000kg) and represents approx. $24,000,000 in revenue per year.

    About Organigram Holdings Inc.

    Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Marihuana for Medical Purposes Regulations.

    On Behalf of the Board of Directors of Organigram,

    Denis Arsenault, Director & CEO

    Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors – including the availability of funds, the results of financing efforts, the results of exploration activities — that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Contact:
    OrganiGram Holdings Inc.
    Brett Allan
    Director of Investor Relations
    (416) 907-4148
    brett@organigram.ca
    www.organigram.ca

    0 1625

    OrganiGram Announces Appointment of President

    MONCTON, NEW BRUNSWICK–(Marketwired – Oct 21, 2014) – OrganiGram Holdings Inc. (TSX VENTURE:OGI) (OGRMF) (the “Company“) is pleased announce the appointment of Roger Rogers to the position of President, effective immediately.

    “I am pleased to announce the appointment of Mr. Rogers to President of Organigram. I believe his vast experience managing large companies will prove to be a great asset to Organigram during this exciting time of growth and development,” said Denis Arsenault, CEO and Chairman.

    With over 20 years of valuable experience leading successful companies, he has a demonstrated track record of obtaining significant financial and operational efficiencies, with many years focused on strategic planning. Prior to joining Organigram, Mr. Rogers was the Vice-President of Finance, Supply Chain & HR at GanongBros. Ltd., a privately held manufacturing company founded in 1873. Mr. Rogers also held the position of Vice President at Moosehead Breweries Ltd. from 2005 to 2012. Mr. Rogers attained his professional CPA designation and completed his MBA at Saint Mary’s University in Halifax, Nova Scotia.

    “I am extremely pleased and excited to join the Organigram team,” said Mr. Rogers. “This is a great opportunity and I look forward to helping the company grow, developing the required internal systems and becoming the market leader in our growing industry.”

    About Organigram Holdings Inc.

    Organigram Holdings Inc. is a TSX Venture Exchange listed company who’s wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Marihuana for Medical Purposes Regulations.

    Please visit www.organigram.ca for more information.

    On Behalf of the Board of Directors of Organigram,

    Denis Arsenault, Chief Executive Officer

    Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    Contact:
    Brett Allan
    Director of Investor Relations
    OrganiGram Holdings Inc.
    (416) 907-4148
    brett@organigram.ca

    Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

    We are your #1 source for all things Marijuana Stocks, Subscribe Below!

    Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
    Ad Placements